Drug Profile

EXG 110

Alternative Names: EXG-110

Latest Information Update: 18 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Exegenesis Bio
Class Gene therapies
Mechanism of Action Alpha-galactosidase replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Fabry's disease
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Clinical Phase Unknown Fabry's disease

Most Recent Events

18 Feb 2025 Hangzhou Jiayin Biotech plans a phase I/II trial for Fabry disease in China (IV, Injection) in March 2025 (NCT06819514)
10 Dec 2024 EXG 110 is available for licensing as of 10 Dec 2024. https://exegenesisbio.com/partnering-business-development/
03 Dec 2024 EXG 110 receives Orphan Drug status for Fabry's disease in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com